99 related articles for article (PubMed ID: 20646644)
1. [Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon DU145 prostate cancer cells].
Zhang ZY; Zhou LQ; Ding Y; Yang L
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):959-61. PubMed ID: 20646644
[TBL] [Abstract][Full Text] [Related]
2. [Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon human nasopharyngeal carcinoma cell line HNE1].
Huang WL; Li XY; Wang HB; Lin W; Lin WZ; Lin SL; Lin YC
Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(16):1133-7. PubMed ID: 22781776
[TBL] [Abstract][Full Text] [Related]
3. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.
Neville-Webbe HL; Evans CA; Coleman RE; Holen I
Tumour Biol; 2006; 27(2):92-103. PubMed ID: 16582586
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines.
Asbagh LA; Uzunoglu S; Cal C
Int Braz J Urol; 2008; 34(3):355-63; discussion 364. PubMed ID: 18601766
[TBL] [Abstract][Full Text] [Related]
6. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation.
Coxon JP; Oades GM; Kirby RS; Colston KW
BJU Int; 2004 Jul; 94(1):164-70. PubMed ID: 15217454
[TBL] [Abstract][Full Text] [Related]
9. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
[TBL] [Abstract][Full Text] [Related]
11. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
Zhou Z; Guan H; Duan X; Kleinerman ES
Cancer; 2005 Oct; 104(8):1713-20. PubMed ID: 16121404
[TBL] [Abstract][Full Text] [Related]
13. Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination.
Sanli UA; Gorumlu G; Erten C; Gul MK; Cengiz E; Kucukzeybek Y; Karaca B; Atmaca H; Uzunoglu S; Karabulut B; Uslu R
Cell Biol Int; 2009 Nov; 33(11):1165-72. PubMed ID: 19716895
[TBL] [Abstract][Full Text] [Related]
14. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?
Michailidou M; Brown HK; Lefley DV; Evans A; Cross SS; Coleman RE; Brown NJ; Holen I
J Vasc Res; 2010; 47(6):481-93. PubMed ID: 20431297
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R
Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299
[TBL] [Abstract][Full Text] [Related]
16. Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.
Gui Q; Xu C; Li D; Zhuang L; Xia S; Yu S
Mol Med Rep; 2015 Sep; 12(3):4243-4249. PubMed ID: 26081451
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
18. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.
Varol U; Degirmenci M; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Sanli UA; Uslu R
Tumour Biol; 2015 Feb; 36(2):779-86. PubMed ID: 25293519
[TBL] [Abstract][Full Text] [Related]
20. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines.
Karabulut B; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Uslu R
Mol Biol Rep; 2011 Jan; 38(1):249-59. PubMed ID: 20349282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
